Navigation Links
Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles

INDIANAPOLIS, Oct. 30, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice president of enterprise risk management effective Jan. 1, 2013. Barnes will replace Anne Nobles, who will retire at the end of the year.

Barnes, vice president and deputy general counsel, is currently responsible for litigation, compliance and specialty legal areas, including regulatory and human resources. In her new role, Barnes will report to John Lechleiter, Ph.D., chairman, president and CEO, and will serve on the company's executive committee.

"Melissa's legal background and extensive experience at Lilly make her the right person to assume this important role within our company," said Lechleiter.  "Lilly is committed to conducting our business with the highest level of integrity and in full compliance with the laws and regulations that govern our operations. Having someone with Melissa's qualifications lead our ethics and compliance organization is evidence of this commitment."  

Barnes is a graduate of Harvard Law School. She joined the company in 1994 and has served in a number of legal and business positions at Lilly, specializing in legal work related to compliance, litigation, human resources, regulatory, business management strategy, and global marketing and sales.

Nobles joined Lilly in 1990 and has served in various leadership positions, including vice president of corporate affairs.  She became Lilly's chief compliance officer in 2007 and has served on the company's executive committee since 2009.

"Anne has provided critical leadership at a very important time for our company," said Lechleiter. "Her contributions have been instrumental in building a comprehensive company-wide ethics and compliance program. She has worked closely with Lilly business leaders to ensure that compliance is effectively integrated into our business plans and our day-to-day activities."

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at  C-LLY



SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
2. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
3. Lilly Announces Results From Lung Cancer Study
4. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
5. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
6. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
7. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
8. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
Post Your Comments:
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 02, 2015 , ... Ruth Pearson ... brutal lupus flare-up. Unable to walk without assistance and quickly losing hope of recovering ... then a miracle happened. , Pearson was attending a women’s retreat when she experienced ...
(Date:12/1/2015)... ... December 01, 2015 , ... The Multiple System Atrophy Coalition ... funds for Multiple System Atrophy (MSA) research, timed today to coincide with Giving Tuesday ... from patients including their ability to work and be productive, to do simple daily ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Royal River Natural ... new study that found post-menopausal women who took the nutritional supplement creatine, along with ... who trained but did not take creatine. , The report is part of the ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... 01, 2015 , ... December 1, 2015 -- InstantLabs is ... growing product line of food safety and seafood fraud prevention tools. , The ... allow InstantLabs to offer fast, reliable species identification for the four most popular ...
Breaking Medicine News(10 mins):